Dapagliflozin-022, identified by its CAS number 2183515-32-2, is a chemical compound that belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. These compounds are primarily utilized in the management of type 2 diabetes mellitus by promoting the excretion of glucose through the urine, thereby lowering blood glucose levels. Dapagliflozin-022 exhibits properties typical of SGLT2 inhibitors, including the ability to enhance glycemic control, reduce body weight, and potentially lower blood pressure. The compound is characterized by its specific molecular structure, which includes functional groups that facilitate its interaction with the SGLT2 protein. Additionally, it may possess pharmacokinetic properties that influence its absorption, distribution, metabolism, and excretion in the body. As with other medications in this class, monitoring for side effects such as urinary tract infections and dehydration is essential during treatment. Overall, Dapagliflozin-022 represents a significant advancement in diabetes therapy, contributing to improved patient outcomes.

Dapagliflozin-022

2183515-32-2: Dapagliflozin-022, identified by its CAS number 2183515-32-2, is a chemical compound that belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. These compounds are primarily utilized in the management of type 2 diabetes mellitus by promoting the excretion of glucose through the urine, thereby lowering blood glucose levels. Dapagliflozin-022 exhibits properties typical of SGLT2 inhibitors, including the ability to enhance glycemic control, reduce body weight, and potentially lower blood pressure. The compound is characterized by its specific molecular structure, which includes functional groups that facilitate its interaction with the SGLT2 protein. Additionally, it may possess pharmacokinetic properties that influence its absorption, distribution, metabolism, and excretion in the body. As with other medications in this class, monitoring for side effects such as urinary tract infections and dehydration is essential during treatment. Overall, Dapagliflozin-022 represents a significant advancement in diabetes therapy, contributing to improved patient outcomes.

CAS 2183515-32-2

Dapagliflozin-022

Dapagliflozin Dimethoxy Impurity

Ref: ST-EA-CP-D8081